// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























4337 Abstracts

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Murielle Roussel - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

AL Amyloidosis

Dexamethasone

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Kushani Ediriwickrema - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Plasmacytoma

Dexamethasone

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

R Donald Harvey - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

Dexamethasone

Characteristics and Safety Profile in Patient Received Ixazomib in China: Interim Analysis of a National, Prospective, Non-Interventional Study of Using Ixazomib in Real-World Clinical Practice (INFINITE Study)

Chengcheng Fu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Treatment Profile of CAR-T Cell Therapy Induced Cytokine Release Syndrome and Neurotoxicity: Insights from Real-World Evidence

Kyeryoung Lee - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

Dexamethasone

Anti-CD 19 CAR-T Cell Therapy with Tisagenlecleucel for Ritcher Syndrome

Iloabueke Chineke - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic Lymphocytic Leukemia

Dexamethasone

Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience

Sheeba Ba Aqeel - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Dexamethasone

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Giulia Rivoli - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Blastic plasmacytoid dendritic cell neoplasm

Dexamethasone

Clinical and Mechanistic Relationship of T-Cell Large Granular LymphocyticLeukemia (TLGL) andmonoclonal Gammopathy of Undetermined Significance(MGUS)

Danai Dima - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Waldenstrom’s macroglobulinemia

Dexamethasone

Adrenal Insufficiency After Glucocorticoid Use in the Pediatric Intensive Care Unit

Ashley N. Radig - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Addison's disease

Dexamethasone

Contemporary Practice of Dexamethasone to Facilitate Extubation in Extremely Premature Infants and Effectiveness of Repeated Courses of Dexamethasone

Rajesh Pandey - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dexamethasone

Impact of Antenatal Corticosteroids on Neonatal Outcome among Very Preterm Infants Born to Mothers with Chorioamnionitis: a Multicenter Cohort Study

Qingqing Lin - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Congenital anomalies

Dexamethasone

Impact of low dose dexamethasone for lung disease in preterm infants on ductal shunting and cardiac indices: A prospective echocardiographic study

Arvind Sehgal - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dexamethasone

Machine Learning Algorithm for Prediction of Neonatal Mortality in Zambia

Albert Manasyan - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Spontaneous abortion

Dexamethasone

Tastes great, less filling! Comparison of oral dexamethasone preparations for children with asthma and croup

Andrea Goettel - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Dexamethasone

The Role of Khdc3 in Oocyte Small RNA Expression

Matthew Smith-Raska - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dexamethasone

Copyright © 2026. QuantiNova All rights reserved